BMAC – Biopharmaceutical Manufacturer's Advisory Council
An initiative by leading Biopharmaceutical companies in the world to establish Singapore as the country of choice for global biomedical sciences manufacturing.
First four investments of new program created to support clinical-stage biotechnology companies
The companies will supply doses to Singapore through 2021 following emergency use authorization from U.S. Food and Drug Administration and interim authorization for pandemic supply from Singapore Health Sciences Authority
Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines
AbbVie’s identity is shaped by the work we do – producing innovative medicines, continually investing in our pipeline, and giving back to create healthier, more vibrant communities.
Our purpose is profound, and our path is clear. We know we are at our best when all voices are heard and valued, and when our employees can contribute their best.
The new AbbVie will be a well-diversified leader in many important therapeutic categories, with both on-market and pipeline assets, and our financial strength will allow us to continue to invest in innovative science and continue to serve unmet medical needs of patients that rely upon us.
Lonza Singapore’s Cell Gene Technologies (CGT) operates multiple purpose-built GMP-qualified production suites for the manufacture of Cell Therapy products designated for clinical trials and commercial use.
Our Development Services Team performs laboratory work that enables our customers to create mammalian cell culture processes, used to produce novel therapeutic proteins.
As the biopharmaceutical industry has evolved over the past 2 decades, Lonza has matched its evolution.
Our R&D engine has produced exciting new molecular entities (NMEs) across our core Therapeutic Areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology.